CD8A and Miyoshi myopathy: To compare the efficacy of the 4-1BB and CD28 co-stimulatory domains in targeting CAR-T cells to MM, we engineered second-generation FCRL5 CARs featuring CD8α stalks and either the 4-1BB (BBζ) or CD28 (28ζ) domain (Fig. 3a).